Vardenafil: A new approach to the treatment of erectile dysfunction |
| |
Authors: | Wayne J G Hellstrom MD |
| |
Institution: | (1) Department of Urology, Section of Andrology, Tulane University Medical Center, 1430 Tulane Avenue, SL-42, 70112 New Orleans, LA, USA |
| |
Abstract: | Vardenafil is a phosphodiesterase type-5 (PDE-5) inhibitor developed as an oral therapy for erectile dysfunction (ED). Multiple
phase 3 clinical trials have been completed and vardenafil is expected to launch worldwide in 2003. Two pivotal, randomized,
double-blind, multicenter studies have evaluated the use of vardenafil in men with ED. Vardenafil improved the rate of achieving
and maintaining an erection during sexual intercourse. Improvement also was noted in other aspects of sexual function, including
confidence, orgasmic function, and overall satisfaction. Vardenafil produces clinically and statistically significant improvements
in erectile function regardless of age, baseline severity, and etiology and is efficacious for the treatment of ED in diabetic
and postprostatectomy patients. Vardenafil has a rapid onset of action and completion of successful sexual intercourse is
possible for some patients 16 minutes after its administration. Twenty milligrams of vardenafil has sustained long-term efficacy
by providing up to 92% of patients with improved erections during more than 2 years of treatment. Vardenafil is well tolerated,
with an adverse event profile typical of the class of PDE-5 inhibitors. The most common adverse events were headache, flushing,
rhinitis, and dyspepsia, which were mild or moderate and generally decreased with continued treatment. Vardenafil may be associated
with transient reductions in blood pressure and commensurate increases in heart rate, with the overall incidence of cardiovascular-related
adverse events similar to that of placebo. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|